Keep up with Primrose Bio’s latest news

Primrose Bio Launches Two RNA Polymerases for High-Quality, Low-Cost mRNA

Oct 14, 2026

Primrose Bio launched Prima RNApols® Cap AG and Prima RNApols® 7 Pro, two RNA polymerases that improve protein expression, capping efficiency and dsRNA reduction in mRNA production.

Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

Sep 22, 2026

Primrose Bio closed a financing round led by new investor Signet Healthcare Partners, with participation from 1315 Capital, Ligand Pharmaceuticals, LDV Partners and Agent Capital.

Primrose Bio Awarded NIH Grant to Develop Genetic Medicine Drug Design Technology

Jul 15, 2026

A $2 million, 24-month SBIR award from NIH’s NCATS funds development of synthetic noncoding sequence elements to improve DNA- and RNA-based medicines.

Intravacc and Primrose Bio Renew Partnership to Enhance Conjugate Vaccine Development

Jun 1, 2026

Intravacc and Primrose Bio renewed their partnership, pairing PeliCRM197® carrier protein with Intravacc’s conjugation and manufacturing know-how.

Primrose Bio Function Generator™ Combinatorial Genetic Technology Case Study Published in PNAS

Apr 8, 2026

A peer-reviewed study in PNAS shows how Function Generator™ combinatorial gene fusion engineers complex microbial traits from tens of millions of gene combinations.

Primrose Bio Launches Prima RNApols Cap AU, a Next-Gen RNA Polymerase for Self-Amplifying mRNA

Nov 10, 2025

Prima RNApols Cap AU is an RNA polymerase for self-amplifying mRNA that produces high-yield, fully capped mRNA with less capping reagent and lower dsRNA.

Primrose Bio Names Drew Burch as CEO

Oct 1, 2025

Drew Burch is appointed CEO and joins the Board. Helge Zieler, PhD, becomes Chief Technology Officer.

Primrose Bio to Collaborate with Serum Institute of India to Develop a Novel Multi-Antigen Vaccine

Jan 10, 2025

Primrose Bio and Serum Institute of India will develop a novel multi-antigen vaccine, with Primrose Bio building the manufacturing strains using Pfenex Expression Technology.

Primrose Bio and ExPLoRNA Therapeutics Announce Strategic Partnership to Advance mRNA Medicines

Sep 3, 2024

Primrose Bio and ExPLoRNA Therapeutics formed a strategic partnership to jointly develop and market products for mRNA medicines.

Primrose Bio Announces Investment from 1315 Capital to Advance Manufacturing Solutions for Next-Generation Therapeutics

Jun 17, 2024

An equity investment from 1315 Capital funds continued development and commercial expansion of Primrose Bio’s manufacturing technologies, including Prima RNApols™.

Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development

Mar 28, 2024

Intravacc and Primrose Bio partner on conjugate vaccines, pairing PeliCRM197® carrier protein with Intravacc’s conjugation and manufacturing know-how.